This switch also occurs in vitro by treating MDA-MB-231 cells with ET1. In breast carcinoma patients, DLX2 expression is associated with increased disease-free survival, while expression of DLX5 is present in a small number of particularly aggressive cases. This evidence concerns the gene DLX2 and breast carcinoma.